Discovery of mesothelin and exploiting it as a target for immunotherapy

Cancer Research

Volumn 74, Issue 11, 2014, Pages 2907-2912

  Pastan, Ira ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMATUXIMAB; ANTIBODY CONJUGATE; BAY 94 9343; CANCER VACCINE; CHIMERIC ANTIBODY; CISPLATIN; CRS 207; CYCLOPHOSPHAMIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOTOXIN; IMMUNOTOXIN SS1P; MESOTHELIN; PEMETREXED; PENTOSTATIN; RG 7787; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTIBODY RESPONSE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL THERAPY; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MESOTHELIOMA; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA MESOTHELIOMA; PLEURISY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; ANIMAL; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; MEMBRANE GLYCOPROTEINS; MOLECULAR TARGETED THERAPY;

EID: 84902124061     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0337     Document Type: Review

References (21)

1. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
2. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-68.
3. Chang K, Pastan I, Willingham M. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinoma. Int J Cancer 1992;51: 548-54.
4. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 1993;27:1418-28.
5. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
6. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is over-expressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
7. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012;133:799-804.
8. Ren YR, Patel K, Paun BC, Kern SE. Structural analysis of the cancerspecific promoter in mesothelin and in other genes overexpressed in in cancers. J Biol Chem 2011;286:11960-9.
9. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
10. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994;269:805-8.
11. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenografts expressing mesothelin. Int J Cancer 1999;80:559-63.
12. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Antitumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000;23:473-9.
13. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669-74.
14. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotech 1999;17:568-72.
15. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
16. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
17. Hassan R, Remaley A, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
18. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15: 1751.
19. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-15.
20. Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, et al. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med 2012;50:721-5.
21. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.